Skip to Main content Skip to Navigation
Journal articles

Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice

Abstract : Drug repurposing has the advantage of shortening regulatory preclinical development steps. Here, we screened a library of drug compounds, already registered in one or several geographical areas, to identify those exhibiting antiviral activity against SARS-CoV-2 with relevant potency. Of the 1,942 compounds tested, 21 exhibited a substantial antiviral activity in Vero-81 cells. Among them, clofoctol, an antibacterial drug used for the treatment of bacterial respiratory tract infections, was further investigated due to its favorable safety profile and pharmacokinetic properties. Notably, the peak concentration of clofoctol that can be achieved in human lungs is more than 20 times higher than its IC 50 measured against SARS-CoV-2 in human pulmonary cells. This compound inhibits SARS-CoV-2 at a post-entry step. Lastly, therapeutic treatment of human ACE2 receptor transgenic mice decreased viral load, reduced inflammatory gene expression and lowered pulmonary pathology. Altogether, these data strongly support clofoctol as a therapeutic candidate for the treatment of COVID-19 patients.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03741914
Contributor : François TROTTEIN Connect in order to contact the contributor
Submitted on : Tuesday, August 2, 2022 - 8:41:05 AM
Last modification on : Thursday, August 4, 2022 - 3:41:05 AM

Identifiers

Collections

Citation

Sandrine Belouzard, Arnaud Machelart, Valentin Sencio, Thibaut Vausselin, Eik Hoffmann, et al.. Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice. PLoS Pathogens, Public Library of Science, 2022, 18 (5), pp.e1010498. ⟨10.1371/journal.ppat.1010498⟩. ⟨inserm-03741914⟩

Share

Metrics

Record views

5

Files downloads

11